Goncalves, Rodrigo
DeSchryver, Katherine
Ma, Cynthia
Tao, Yu
Hoog, Jeremy
Cheang, Maggie
Crouch, Erika
Dahiya, Neha
Sanati, Souzan
Barnes, Michael
Sarian, Luis Otávio Zanatta
Olson, John
Allred, Donald Craig
Ellis, Matthew J.
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Avon Foundation for Women
Foundation for Barnes-Jewish Hospital
Breast Cancer Research Foundation
National Cancer Institute (P50 CA68438)
National Institutes of Health (R01 CA095614)
Article History
Received: 29 May 2017
Accepted: 1 June 2017
First Online: 13 June 2017
Compliance with ethical standards
:
: Dr. Matthew Ellis has stock ownership of Bioclassifier LLC and Prosigna Nanostring. Dr. Matthew Ellis receives consultant fees from AstraZeneca, Novartis and Pfizer. Dr. Michael Barnes is an employee and has stock ownership at Roche/Ventana medical systems. The other authors declare that they have no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: was obtained from all individual participants included in the study.